

Tomasetti, Inc., Washington, DC; Toyon Research Corporation, Goleta, CA; Transtecs Corporation, Arlington, VA; Triton Systems, Inc., Chelmsford, MA; Ultra Electronics Ocean Systems, Inc., Braintree, MA; UnderSea Sensor Systems, Inc. (USSSI), Columbia City, IN; University of Florida Board of Trustees, Gainesville, FL; University of Rhode Island, Kingston, RI; Viasat, Inc., Carlsbad, CA; Visionary Products, Inc. (dba VPI Technology Group), Draper, UT; Welkins LLC, Downers Grove, IL; Woods Hole Oceanographic Institution, Woods Hole, MA; and World Wide Technology, Maryland Heights, MO.

The general area of UTIC's planned activity is conducting research, development and testing in cooperation with the Government leading to technology demonstrations in undersea and maritime technology applications and solutions through the following technology areas: Sensors and Sonar; Platform and Payload Integration; Undersea Distributed Networked Systems; Electronics/Optics/Materials; Passive Sensing; Undersea Satellites; Energy Storage and Release; Virtualization; Machine Learning; Threat Monitoring and Prediction; Cooperative Force Torpedo Defense; Undersea Warfare Analysis; Multi-Domain Fusion; Electronic Warfare; Distributed and Autonomous Sensors; USW Weapons and Autonomous Vehicles; Autonomy; Quantum Computing; Bio-Inspired Sensors; Environmental Sensing, Monitoring and Prediction; In-Situ Energy Sources; and Multi-Dimensional Display.

**Suzanne Morris,**

*Chief, Premerger and Division Statistics Unit  
Antitrust Division.*

[FR Doc. 2018-23984 Filed 11-1-18; 8:45 am]

**BILLING CODE 4410-11-P**

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### **Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group on Corrosion Under Insulation**

Notice is hereby given that, on October 4, 2018, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Southwest Research Institute—Cooperative Research Group on Cooperative Research Group on Corrosion Under Insulation ("CUI-JIP") has filed written notifications simultaneously with the Attorney General and the Federal Trade

Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, The Dow Chemical Company, Freeport, TX, has been added as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and CUI-JIP intends to file additional written notifications disclosing all changes in membership.

On March 22, 2018, CUI-JIP filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on April 24, 2018 (83 FR 17851).

The last notification was filed with the Department on September 6, 2018. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on September 17, 2018 (83 FR 46972).

**Suzanne Morris,**

*Chief, Premerger and Division Statistics Unit,  
Antitrust Division.*

[FR Doc. 2018-23988 Filed 11-1-18; 8:45 am]

**BILLING CODE 4410-11-P**

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### **Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group on ROS-Industrial Consortium-Americas**

Notice is hereby given that on September 28, 2018, Pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Southwest Research Institute—Cooperative Research Group on ROS-Industrial Consortium-Americas ("RIC-Americas") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Stratasys, Inc., Eden Prairie, MN, and Cognex Corporation, Natick, MA, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned

activity of the group research project. Membership in this group research project remains open, and RIC-Americas intends to file additional written notifications disclosing all changes in membership.

On April 30, 2014, RIC-Americas filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on June 9, 2014 (79 FR 32999).

The last notification was filed with the Department on August 17, 2018. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on September 4, 2018 (83 FR 44904).

**Suzanne Morris,**

*Chief, Premerger and Division Statistics Unit,  
Antitrust Division.*

[FR Doc. 2018-23983 Filed 11-1-18; 8:45 am]

**BILLING CODE 4410-11-P**

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### **Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical Technology Enterprise Consortium**

Notice is hereby given that, on October 12, 2018, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Medical Technology Enterprise Consortium ("MTEC") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Specifically, 8i Labs, Inc., Los Angeles, CA; Adaptive Phage Therapeutics, Inc. (Aphage), Gaithersburg, MD; Aleo BME, Inc., State College, PA; American Defense International (ADI), Washington, DC; Aptima, Inc., Woburn, MA; Atlantic Diving Supply, Inc. (ADS), Virginia Beach, VA; Benchmark Electronics, Inc., Scottsdale, AZ; BioMojo LLC, Cary, NC; BioSpyder Technologies, Inc., Carlsbad, CA; Brain Mapping Foundation, West Hollywood, CA; Brain Power, LLC, Cambridge, MA; BrainScope Company, Inc., Bethesda, MD; CAE Healthcare, Inc., Sarasota, FL; Carmell Therapeutics Corporation, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Cell Guidance Systems Ltd.,

Cambridge, UK; Clear Scientific, LLC, Cambridge, MA; Cornerstone Government Affairs, Inc., Washington, DC; DePuy Synthes Products, Inc., Raynham, MA; Dignitas Technologies, Orlando, FL; ECM Therapeutics, Inc., Warrendale, PA; ElMindA Ltd., Herzliya, Israel; Family Health International DBA FHI 360, Durham, NC; Hypatia Project, Reston, VA; Institutes for Behavior Resources, Inc. (IBR), Baltimore, MD; Integrated MicroSciences, LLC, Frederick, MD; J. Craig Venter Institute (JCVI), Rockville, MD; KaloCyte, Inc., St. Louis, MO; Lieber Institute, Inc., Baltimore, MD; NanoDirect, LLC, Baltimore, MD; OXYVITA, Inc., Middletown, NY; Parsons Government Services, Inc., Pasadena, CA; Protocentral, Inc., Woburn, MA; Q2Pharma, Haifa, Israel; RAIN Scientific, Inc., Asheville, NC; Rehat, LLC, Pittsburgh, PA; Research Foundation for Mental Hygiene, Inc. (NYSPI), New York, NY; Responde2 Corporation, Mountain View, CA; Saint Barnabas Medical Center (SBMC), Livingston, NJ; San Diego Blood Bank, San Diego, CA; SmartMD Systems, Inc., Manchester Center, VT; Sonica LLC, Evanston, IL; Spire, San Francisco, CA; Syracuse University, Syracuse, NY; The Charles Stark Draper Laboratory, Inc. (Draper), Cambridge, MA; The University of Arizona, Defense and Security Research Institute (DSRI), Tucson, AZ; Trauma Insight, LLC, San Antonio, TX; Trustees of Boston University, Boston, MA; University of Central Florida Research Foundation, Inc., Orlando, FL; University of Houston—Cullen College of Engineering, Houston, TX; Vivonics, Inc., Bedford, MA; and Washington State University, Pullman, WA; have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MTEC intends to file additional written notifications disclosing all changes in membership.

On May 9, 2014, MTEC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on June 9, 2014 (79 FR 32999).

The last notification was filed with the Department on May 3, 2018. A notice was published in the **Federal**

**Register** pursuant to Section 6(b) of the Act on June 19, 2018 (83 FR 28448).

**Suzanne Morris**,  
*Chief, Premerger and Division Statistics Unit  
Antitrust Division.*

[FR Doc. 2018–23989 Filed 11–1–18; 8:45 am]

**BILLING CODE 4410–11–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–392]

**Bulk Manufacturer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** The registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturers of various classes of schedule I and II controlled substances.

**SUPPLEMENTARY INFORMATION:** The companies listed below applied to be registered as bulk manufacturers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted for these notices.

Company	FR citation	Published
Chemtos, LLC.	83 FR 37520	August 1, 2018.
Johnson Matthey Inc.	83 FR 34880	July 23, 2018.
AMRI Rensselaer, Inc.	83 FR 38179	August 3, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of these registrants to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed companies.

Dated: October 24, 2018.

**John J. Martin**,

*Assistant Administrator.*

[FR Doc. 2018–24005 Filed 11–1–18; 8:45 am]

**BILLING CODE 4410–09–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–392]

**Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals, Inc.**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 2, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on September 13, 2018, Janssen Pharmaceuticals, Inc., Buildings 1–5 & 7–14, 1440 Olympic Drive, Athens, Georgia 30601 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Methylphenidate .....	1724	II
Hydromorphone .....	9150	II
Hydrocodone .....	9193	II
Oripavine .....	9330	II
Thebaine .....	9333	II
Tapentadol .....	9780	II